PROGRESSIVE PULMONARY FIBROSIS

This study looks at the long-term safety of a daily pill called nerandomilast for people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). About 1,700 adults who finished a previous nerandomilast study can join. They take the drug for up to 22 mont…

This study looks at the long-term safety of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. The goal is to monitor side effects and lung function over time, not to cure the…

This study tests whether a daily dose of quercetin, a natural compound found in foods like apples and onions, can slow lung scarring and improve breathing in people with pulmonary fibrosis. Researchers will compare 50 patients taking quercetin plus standard care against 50 patien…

This study tests an inhaled version of the drug pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their u…

This study tests whether an inhaled drug called treprostinil can slow the decline in lung function for people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. About 698 adults with PPF will receive either the drug or a placebo for 52 w…

This study is testing whether a mobile app called SUPPORT-T can help people with progressive pulmonary fibrosis (a type of lung scarring) and their caregivers get easier access to palliative care — care that focuses on comfort and quality of life. About 170 patients and their car…

This study looks at how anti-fibrotic medications affect body composition in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Researchers will use bioelectrical impedance analysis (BIA) and muscle ultrasound to measure muscle and fat change…

This study tests a new way to manage follow-up care for people with interstitial lung disease (ILD). Instead of making multiple trips for tests and doctor visits, patients in the optimized group get everything done in one coordinated hospital visit. The goal is to see if this red…

This study follows 500 adults with non-IPF lung scarring (interstitial lung disease) for 24 months. Researchers collect health data, images, and samples to improve how progressive pulmonary fibrosis is classified and predicted. The goal is to better understand the disease, not to…